Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers
NCT ID: NCT04328766
Last Updated: 2021-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2020-09-06
2020-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects
NCT05812404
Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers
NCT02369302
Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Formulations in Healthy Adult Volunteers
NCT04688580
A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152
NCT02502721
An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers
NCT05832697
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DWP14012 Cohort A
DWC202005, alone
DWC202005, as a single dose
DWP14012 Cohort B
DWP14012 + DWC202005
DWP14012 and DWC202005, as a single dose
DWP14012 Cohort C
DWP14012 + DWC202005, after multiple doses of DWP14012
DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DWC202005, alone
DWC202005, as a single dose
DWP14012 + DWC202005
DWP14012 and DWC202005, as a single dose
DWP14012 + DWC202005, after multiple doses of DWP14012
DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of understanding provided information and complying with protocol requirements
* Provide written informed consent to participate in the study
19 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network (QPharm)
Queensland, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWP14012106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.